Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2009-07-06
2009-11-10
Benzion, Gary (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S024310, C536S024330
Reexamination Certificate
active
07615353
ABSTRACT:
A diagnostic method for predicting quantitatively whether a human tumor will be responsive or resistant (non-responsive) to treatment with the VEGF inhibitor, tivozanib (AV-951), is disclosed. The test is based on application of an algorithm to measurements of expression levels of the genes in a predictive gene set.
REFERENCES:
patent: 2007/0264193 (2007-11-01), Shojaei et al.
patent: WO-2007/028005 (2007-03-01), None
patent: WO-2008/128008 (2008-10-01), None
Arao et al., 2005,Int J. Cancer118:483-489.
Ayers et al., “Discovery and Validation of Biomarkers that Respond to Treatment with Brivanib Alaninate, a Small-Molecule VEGFR-2/FGFR-1 Antagonist,” 2004,Cancer Research64:7857- 7866.
Duncan et al., 2008,Clin. Cancer Res.14:3030-3035.
Golshayan et al., “Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies,” 2008, Future Oncol. 4:85-92.
Longo et al., “Anti-VEGF therapy: the search for clinical biomarkers,” 2008,Expert Rev. Mol. Diag.8:301-314.
Murdoch et al., “The role of myeloid cells in the promotion of tumour angiogenesis,” 2008,Nature Reviews Cancer8:618-631.
Shojaei et al., “G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models,” 2009,Proc. Nat'l. Acad. Sci. USA106:6742-6747.
Shojaei et al., “Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+myeloid cells,” 2007,Nature Biotechnology25:911-920.
Feng Bin
Lin Jie
Robinson Murray
Sun Wenping Kathryn
AVEO Pharmaceuticals, Inc.
Benzion Gary
Creason Gary L.
Woolwine Samuel
LandOfFree
Tivozanib response prediction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tivozanib response prediction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tivozanib response prediction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142573